Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
139 hedge funds and large institutions have $1.3B invested in Tetraphase Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 68 increasing their positions, 30 reducing their positions, and 15 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 30
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
39% more capital invested
Capital invested by funds: $937M → $1.3B (+$363M)
7% more funds holding
Funds holding: 130 → 139 (+9)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less call options, than puts
Call options by funds: $8.1M | Put options by funds: $8.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.7M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$14.7M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$11.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$17.1M |
| 2 |
GAMA
Graticule Asia Macro Advisors
New York
|
-$10.6M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$8.48M |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
-$4.86M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.5M |
TTPH Hedge Fund Activity: Q2 2015 in Review
139 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q2 2015, worth a combined $1.3B — up 39% from $937M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TTPH positions and 15 closed out — a net gain of 9 holders — while 68 added to existing stakes and 30 trimmed.
The largest buyer was Vanguard Group, adding an estimated $18.8M. The largest seller was HealthCor Management, exiting entirely with an estimated $17.1M sold.
- 139 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q2 2015, up from 130 in Q1 2015.
- Funds reported $1.3B of Tetraphase Pharmaceuticals, Inc. stock for Q2 2015, up 39% quarter-over-quarter.
- 24 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q2 2015 and 15 closed out, a net change of +9 holders.
- The largest Tetraphase Pharmaceuticals, Inc. buyer in Q2 2015 was Vanguard Group, an estimated $18.8M added.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q2 2015 was HealthCor Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2015.